Compare Stocks: VTYX, TLX, TNGX, and PBLS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PBLS Parabilis Medicines	$27.48 -2.2%	$36.11	$24.51 ▼ $42.49	$3.39B	N/A	1.30 million shs	1.09 million shs
TLX Telix Pharmaceuticals	$11.21 +1.8%	$11.50	$6.28 ▼ $13.11	$3.81B	-0.17	517,723 shs	313,022 shs
TNGX Tango Therapeutics	$23.81 +5.5%	$24.43	$6.69 ▼ $34.39	$4.01B	1.17	3.45 million shs	3.10 million shs
VTYX Ventyx Biosciences	$14.00	$13.98	$0.78 ▼ $25.00	$1.00B	1.26	3.32 million shs	5.45 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PBLS Parabilis Medicines	0.00%	-9.25%	-24.34%	-10.11%	+2,747,999,900.00%
TLX Telix Pharmaceuticals	0.00%	+6.26%	-5.80%	+0.63%	+9.47%
TNGX Tango Therapeutics	0.00%	+2.45%	+1.88%	-23.34%	+244.57%
VTYX Ventyx Biosciences	0.00%	0.00%	0.00%	0.00%	+265.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PBLS Parabilis Medicines	$27.48 -2.2%	$36.11	$24.51 ▼ $42.49	$3.39B	N/A	1.30 million shs	1.09 million shs
TLX Telix Pharmaceuticals	$11.21 +1.8%	$11.50	$6.28 ▼ $13.11	$3.81B	-0.17	517,723 shs	313,022 shs
TNGX Tango Therapeutics	$23.81 +5.5%	$24.43	$6.69 ▼ $34.39	$4.01B	1.17	3.45 million shs	3.10 million shs
VTYX Ventyx Biosciences	$14.00	$13.98	$0.78 ▼ $25.00	$1.00B	1.26	3.32 million shs	5.45 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PBLS Parabilis Medicines	0.00%	-9.25%	-24.34%	-10.11%	+2,747,999,900.00%
TLX Telix Pharmaceuticals	0.00%	+6.26%	-5.80%	+0.63%	+9.47%
TNGX Tango Therapeutics	0.00%	+2.45%	+1.88%	-23.34%	+244.57%
VTYX Ventyx Biosciences	0.00%	0.00%	0.00%	0.00%	+265.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PBLS Parabilis Medicines	2.71	Moderate Buy	$41.67	51.63% Upside
TLX Telix Pharmaceuticals	2.80	Moderate Buy	$20.50	82.87% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	82.53% Upside
VTYX Ventyx Biosciences	2.00	Hold	$14.00	N/A

Current Analyst Ratings Breakdown

Latest VTYX, TLX, TNGX, and PBLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/25/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/23/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/21/2026	TLX Telix Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
9/18/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/15/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/14/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/4/2026	PBLS Parabilis Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
9/2/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/20/2026	TLX Telix Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	$803.79M	4.74	$0.04 per share	265.87	$1.23 per share	9.11
TNGX Tango Therapeutics	$62.38M	64.36	N/A	N/A	$2.57 per share	9.26
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$3.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PBLS Parabilis Medicines	-$145.89M	-$2.13	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	41.52	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)
VTYX Ventyx Biosciences	-$135.12M	-$1.50	N/A	N/A	N/A	N/A	-48.11%	-43.89%	N/A

Latest VTYX, TLX, TNGX, and PBLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	TNGX Tango Therapeutics	-$0.3537	N/A	N/A	N/A	$3.28 million	N/A
8/13/2026	Q2 2026	PBLS Parabilis Medicines	-$0.16	-$2.32	-$2.16	-$2.32	N/A	$0.15 million
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PBLS Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PBLS Parabilis Medicines	N/A	17.91	17.91
TLX Telix Pharmaceuticals	1.16	2.01	1.85
TNGX Tango Therapeutics	N/A	50.82	50.82
VTYX Ventyx Biosciences	N/A	17.86	17.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PBLS Parabilis Medicines	N/A
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	78.99%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
PBLS Parabilis Medicines	N/A
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	6.50%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PBLS Parabilis Medicines	145	123.53 million	N/A	N/A
TLX Telix Pharmaceuticals	1,184	339.89 million	N/A	N/A
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable
VTYX Ventyx Biosciences	30	71.76 million	61.36 million	Optionable

VTYX, TLX, TNGX, and PBLS Headlines

Recent News About These Companies

Ventyx Biosciences Shareholders Approve Merger With Eli Lilly

June 12, 2026 | theglobeandmail.com

Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm

April 29, 2026 | globenewswire.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

February 5, 2026 | businesswire.com

Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple

January 26, 2026 | finance.yahoo.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

January 23, 2026 | prnewswire.com

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

January 21, 2026 | globenewswire.com

Halper Sadeh LLC Encourages VTYX, PEN, CWAN Shareholders to Contact the Firm to Discuss Their Rights

January 15, 2026 | caledonianrecord.comC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 15, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 13, 2026 | globenewswire.com

Halper Sadeh LLC Encourages VTYX, ONTF, FFIC, OCFC Shareholders to Contact the Firm to Discuss ...

January 13, 2026 | caledonianrecord.comC

LifeSci Capital Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

January 12, 2026 | theglobeandmail.com

UBS downgrades Ventyx Biosciences (VTYX)

January 10, 2026 | msn.com

Oppenheimer downgrades Ventyx Biosciences (VTYX)

January 9, 2026 | msn.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

January 8, 2026 | prnewswire.com

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

January 8, 2026 | prnewswire.com

Lilly confirms bid to acquire Ventyx Biosciences

January 8, 2026 | thepharmaletter.comT

Canaccord Genuity downgrades Ventyx Biosciences (VTYX)

January 8, 2026 | msn.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

January 8, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 8, 2026 | prnewswire.com

VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders

January 8, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TLX, TNGX, and PBLS Company Descriptions

Parabilis Medicines NASDAQ:PBLS

$27.48 -0.61 (-2.17%)

As of 10/9/2026 04:00 PM Eastern

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Telix Pharmaceuticals NASDAQ:TLX

$11.21 +0.20 (+1.82%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.22 +0.00 (+0.04%)

As of 10/9/2026 07:30 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Tango Therapeutics NASDAQ:TNGX

$23.81 +1.24 (+5.49%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$23.80 -0.01 (-0.05%)

As of 10/9/2026 07:30 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Ventyx Biosciences NASDAQ:VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTYX, TLX, TNGX, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTYX, TLX, TNGX, and PBLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTYX, TLX, TNGX, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TLX, TNGX, and PBLS Company Descriptions

Parabilis Medicines NASDAQ:PBLS

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

Ventyx Biosciences NASDAQ:VTYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTYX, TLX, TNGX, and PBLS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTYX, TLX, TNGX, and PBLS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTYX, TLX, TNGX, and PBLS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TLX, TNGX, and PBLS Company Descriptions

Parabilis Medicines NASDAQ:PBLS

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

Ventyx Biosciences NASDAQ:VTYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools